Suvretta Capital Management LLC Has $41.61 Million Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Suvretta Capital Management LLC boosted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 16.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,913,012 shares of the specialty pharmaceutical company's stock after acquiring an additional 701,007 shares during the quarter. KalVista Pharmaceuticals accounts for about 1.4% of Suvretta Capital Management LLC's investment portfolio, making the stock its 23rd largest holding. Suvretta Capital Management LLC owned 9.94% of KalVista Pharmaceuticals worth $41,613,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $634,000. SG Americas Securities LLC increased its stake in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after buying an additional 1,319 shares during the period. Tower Research Capital LLC TRC lifted its position in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after buying an additional 5,502 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in KalVista Pharmaceuticals by 14.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock worth $5,895,000 after buying an additional 89,001 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of KalVista Pharmaceuticals by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock valued at $1,041,000 after buying an additional 4,940 shares during the period.

Analyst Upgrades and Downgrades

KALV has been the subject of several recent research reports. JMP Securities began coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an "outperform" rating and a $19.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Finally, Jones Trading reissued a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV traded up $0.17 during midday trading on Tuesday, reaching $12.24. The stock had a trading volume of 349,114 shares, compared to its average volume of 421,230. The stock has a market capitalization of $608.52 million, a P/E ratio of -3.36 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50. The firm's fifty day simple moving average is $12.01 and its 200-day simple moving average is $10.44.

Insider Activity

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the sale, the insider now directly owns 106,611 shares of the company's stock, valued at $1,262,274.24. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the sale, the chief executive officer now owns 287,811 shares in the company, valued at $3,445,097.67. This represents a 2.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,647 shares of company stock valued at $181,770. 10.50% of the stock is owned by insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).